Results 1 to 10 of about 8,545 (210)

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients [PDF]

Nature Communications
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 
Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, Maximillian Woodall, Samuel Ellis, Akosua A. Agyeman, Charles Miller, Mercy Okechukwu, Emily Kirkpatrick, Amy I. Jacobs, Charlotte A. Williams, Sunando Roy, Luz M. Martin-Bernal, Rachel Williams, Claire M. Smith, Theo Sanderson, Fiona B. Ashford, Beena Emmanuel, Zaheer M. Afzal, Adrian Shields, Alex G. Richter, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Mark Lown, Nick Francis, Bhautesh Jani, Duncan B. Richards, Najib M. Rahman, Ly-Mee Yu, Nicholas P. B. Thomas, Nigel D. Hart, Philip Evans, Monique Andersson, Gail Hayward, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Paul Little, F. D. Richard Hobbs, Saye Khoo, Christopher Butler, David M. Lowe, Judith Breuer, PANORAMIC Virology Group   +43 more
doaj   +11 more sources

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molecules, 2021
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
Mohd Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq   +2 more
exaly   +3 more sources

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry [PDF]

International Journal of Antimicrobial Agents, 2023
Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates.
Jon Salmanton-García, Francesco Marchesi, Iker Falces-Romero   +2 more
exaly   +5 more sources

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model [PDF]

EBioMedicine, 2021
BACKGROUND: Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently reported in COVID-19 patients.
Rana Abdelnabi, Caroline S Foo, Suzanne J F Kaptein   +2 more
exaly   +3 more sources

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Viruses, 2022
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses.
Ashley Jia Wen Yip, Zheng Yao Low, Vincent T K Chow   +2 more
exaly   +3 more sources

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating.
Ivan Gentilé, Riccardo Scotto, Nicola Schiano Moriello   +2 more
exaly   +3 more sources

SARS-CoV-2 Error Catastrophe Under Molnupiravir: Mutagenic Enhancement Enables Viral Persistence with Impaired Fitness [PDF]

Viruses
Molnupiravir induces mutations that render severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-competent through error catastrophe mechanisms.
Yuriko Tomita, Kaya Miyazaki, Rika Mochizuki, Hideki Hasegawa   +3 more
doaj   +2 more sources

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]

BMC Infectious Diseases
Background COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin, Shwu-Jiuan Lin, Yu-Hui Chang, Fu-Der Wang, Phung-Anh Nguyen, Phan Thanh Phuc, Whitney Burton, Nguyen Thi Kim Hien, Chia-Chieh Lin, Carlos Shu-Kei Lam, To-Chi Ha, Christine Y. Lu, Chih-Wei Huang, Hsuan-Chia Yang, Shiue-Ming Lin, Chieh Yang, Li-Hsuan Wang, Jason C. Hsu   +17 more
doaj   +2 more sources

Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells [PDF]

Pathogens
The cross-species spillover of coronaviruses is considered a serious public health risk. Feline coronavirus (FCoV), canine coronavirus (CCoV), and transmissible gastroenteritis virus (TGEV) are all classified under Alphacoronavirus suis and infect ...
Tomoyoshi Doki, Kazuki Shinohara, Kaito To, Tomomi Takano   +3 more
doaj   +2 more sources

Why Molnupiravir Fails in Hospitalized Patients

mBio, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life.
Ashley N. Brown, Yinzhi Lang, Jieqiang Zhou, Evelyn J. Franco, Kaley C. Hanrahan, Juergen B. Bulitta, George L. Drusano   +6 more
doaj   +3 more sources